BEAM - Beam Therapeutics Inc

-

$undefined

N/A

(N/A)

Beam Therapeutics Inc NASDAQ:BEAM Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Location: | Website: beamtx.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

645.8M

Cash

850.7M

Avg Qtr Burn

-86.81M

Short % of Float

18.14%

Insider Ownership

1.21%

Institutional Own.

79.10%

Qtr Updated

12/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
BEAM-302 Details
Alpha-1 Antitrypsin Deficiency

Phase 1/2

Data readout

BEAM-101 Details
Beta thalessemia, Sickle cell disease

Phase 1/2

Data readout

BEAM-201 Details
Blood cancer, Cancer, T-cell lymphoma, Acute lymphoblastic leukemia

Phase 1/2

Update

BEAM-301 Details
Glycogen Storage Disease Type Ia , Gene & Cell therapies

Phase 1/2

Initiation

BEAM-103 Details
Beta thalessemia, Sickle cell disease

Phase 1

Initiation